News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
First-in-Class Vepdegestrant Approved in Advanced Breast Cancer
The FDA has approved vepdegestrant (Veppanu), the first-in-class oral proteolysis-targeting chimera (PROTAC) estrogen receptor degrader, for adults with advanced or metastatic ER-positive/HER2-negative breast cancer. This approval marks a significant milestone as it introduces an entirely new mechanism of action — targeted protein degradation — to the breast cancer treatment landscape. Vepdegestra…
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC
A publication in Nature Reviews Clinical Oncology highlights that datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, has demonstrated an overall survival benefit when used as first-line treatment in patients with advanced-stage triple-negative breast cancer (TNBC). Overall survival is the gold-standard endpoint in oncology trials, and achieving a statistically significant improvemen…
FDA Panel Endorses Capivasertib Use in Prostate Cancer
An FDA advisory panel voted 7-1, with one abstention, to endorse the use of capivasertib (Truqap) for the treatment of an aggressive subtype of prostate cancer. The Oncologic Drugs Advisory Committee's favorable recommendation signals that full FDA approval may follow in the coming months. Capivasertib is an AKT pathway inhibitor previously approved for breast cancer, and its potential expansion i…
Artificial intelligence model boosts lung nodule diagnostic accuracy in clinical trial
A new artificial intelligence model called DeepFAN has been validated in China's first multi-center clinical trial for pulmonary nodule assessment, demonstrating high diagnostic accuracy in distinguishing malignant from benign lung nodules. Published in Nature Cancer, the study showed that when used as a clinical decision-support tool, DeepFAN substantially improved junior radiologists' diagnostic…
Long-lived immune cells show promise against cancer in world-first trial
A world-first clinical trial has demonstrated that a specialized type of T cell with stem cell-like properties can induce remission in patients with blood cancer. The therapy uses T memory stem cells (Tscm), which are capable of long-term self-renewal in the body, potentially providing durable anti-cancer immune responses unlike conventional T cell therapies that lose potency over time. Some patie…
Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
A study published in the Journal of Clinical Oncology reports the development and validation of an artificial intelligence–powered computational histology biomarker designed to guide chemotherapy selection in patients with advanced pancreatic cancer. The tool analyzes standard pathology tissue slides using AI to predict which patients are most likely to benefit from specific chemotherapy regimens,…
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
A Phase III superiority randomized trial (DELII) published in the Journal of Clinical Oncology evaluated an ultra-low-dose immunotherapy regimen in patients with relapsed or refractory solid tumors, a population with severely limited treatment options. The study demonstrated that dramatically reduced doses of immunotherapy can achieve meaningful clinical benefit compared to control, potentially re…
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
The American Society of Clinical Oncology (ASCO) has published an updated clinical practice guideline on the use of immunotherapy and targeted therapy in advanced gastroesophageal cancer, appearing in the Journal of Clinical Oncology in April 2026. The update consolidates the latest evidence from pivotal trials to redefine recommended treatment sequences, biomarker-driven agent selection, and comb…
New blood test could catch pancreatic cancer before it’s too late
Researchers have developed a novel blood test capable of detecting pancreatic cancer at early stages with over 90% accuracy, potentially transforming outcomes for one of the deadliest malignancies. The test combines two newly discovered blood proteins with existing biomarkers to create a four-marker panel that performs especially well in early-stage disease, when curative treatment is still possib…
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
A study published in the Journal of Clinical Oncology evaluated a tissue-free circulating tumor DNA (ctDNA) assay for predicting patient outcomes in the context of FOLFOX-based adjuvant chemotherapy for colon cancer, using data from the large phase III Alliance N0147 trial. The tissue-free approach is notable because it does not require prior tumor sequencing to design a personalized ctDNA panel, …